DJS Antibodies is a biotechnology startup dedicated to revolutionizing the treatment of chronic inflammatory diseases through the development of novel therapeutic monoclonal antibodies targeting GPCRs. Founded in 2014, the company has made significant strides in unlocking the potential of immunology to deliver groundbreaking medicines. Their proprietary technology has enabled the production of first-in-class antibody therapeutics, offering hope for conditions that were previously deemed untreatable.
Having garnered interest from investors, DJS Antibodies secured a Seed investment on 22 December 2020. While details about the investors remain undisclosed, this investment underscores the potential and promise that the startup holds within the biotechnology, health care, and health and wellness sectors.